176 related articles for article (PubMed ID: 37379366)
1. Host Interactions with Engineered T-cell Micropharmacies.
Bourne CM; Wallisch P; Dacek MM; Gardner TJ; Pierre S; Vogt K; Corless BC; Bah MA; Romero-Pichardo JE; Charles A; Kurtz KG; Tan DS; Scheinberg DA
Cancer Immunol Res; 2023 Sep; 11(9):1253-1265. PubMed ID: 37379366
[TBL] [Abstract][Full Text] [Related]
2. Host-cell Interactions of Engineered T cell Micropharmacies.
Bourne CM; Wallisch P; Dacek M; Gardner T; Pierre S; Vogt K; Corless BC; Bah MA; Romero Pichardo J; Charles A; Kurtz KG; Tan DS; Scheinberg DA
bioRxiv; 2023 May; ():. PubMed ID: 37205431
[TBL] [Abstract][Full Text] [Related]
3. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
4. SEAKER cells coordinate cellular immunotherapy with localized chemotherapy.
Lane IC; Jan M
Trends Pharmacol Sci; 2022 Oct; 43(10):804-805. PubMed ID: 35491262
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
6. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
7. T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors.
Rasoulouniriana D; Santana-Magal N; Gutwillig A; Farhat-Younis L; Tal L; Amar S; Milyavsky M; Muddineni SSNA; Solomon N; Shpilt H; Dotan S; Pilpel N; Waskow C; Feinmesser M; Rider P; Carmi Y
Cancer Immunol Res; 2023 Jun; 11(6):792-809. PubMed ID: 37070661
[TBL] [Abstract][Full Text] [Related]
8. Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells.
Koristka S; Ziller-Walter P; Bergmann R; Arndt C; Feldmann A; Kegler A; Cartellieri M; Ehninger A; Ehninger G; Bornhäuser M; Bachmann MP
Cancer Immunol Immunother; 2019 Sep; 68(9):1401-1415. PubMed ID: 31414180
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
10. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
Chen L; Qiao D; Wang J; Tian G; Wang M
Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
[TBL] [Abstract][Full Text] [Related]
11. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD
Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659
[TBL] [Abstract][Full Text] [Related]
12. Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy.
Jazirehi AR
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769156
[TBL] [Abstract][Full Text] [Related]
13. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
14. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X
J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322
[TBL] [Abstract][Full Text] [Related]
15. Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors.
Du X; Darcy PK; Wiede F; Tiganis T
Mol Cell Biol; 2022 Mar; 42(3):e0044921. PubMed ID: 35041491
[TBL] [Abstract][Full Text] [Related]
16. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.
Matsuda T; Leisegang M; Park JH; Ren L; Kato T; Ikeda Y; Harada M; Kiyotani K; Lengyel E; Fleming GF; Nakamura Y
Clin Cancer Res; 2018 Nov; 24(21):5357-5367. PubMed ID: 29720506
[No Abstract] [Full Text] [Related]
17. T-cell receptor gene therapy of established tumors in a murine melanoma model.
Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
[TBL] [Abstract][Full Text] [Related]
18. Engineering CAR-T cells to activate small-molecule drugs in situ.
Gardner TJ; Lee JP; Bourne CM; Wijewarnasuriya D; Kinarivala N; Kurtz KG; Corless BC; Dacek MM; Chang AY; Mo G; Nguyen KM; Brentjens RJ; Tan DS; Scheinberg DA
Nat Chem Biol; 2022 Feb; 18(2):216-225. PubMed ID: 34969970
[TBL] [Abstract][Full Text] [Related]
19. Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin.
Zhang Z; Liu C; Wang M; Sun R; Yang Z; Hua Z; Wu Y; Wu M; Wang H; Qiu W; Yin H; Yang M
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586774
[TBL] [Abstract][Full Text] [Related]
20. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.
Straetemans T; Coccoris M; Berrevoets C; Treffers-Westerlaken E; Scholten CE; Schipper D; Ten Hagen TL; Debets R
Hum Gene Ther; 2012 Feb; 23(2):187-201. PubMed ID: 21958294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]